Head and neck squamous carcinoma
Conditions
Interventions
Adbelizumab combined with paclitaxel (albumin-bound) and carboplatin:Dabilimab
Sponsors
The First Affiliated Hospital,Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Adults aged 18 to 75, both male and female. 2. All patients must have a pathologically confirmed initial treatment of head and neck squamous cell carcinoma at the First Affiliated Hospital of Sun Yat-sen University, without a history of radiotherapy or chemotherapy for head and neck cancer or immunotargeted drug therapy. 3. Clinical staging: Patients with stage III-IVA/B locally advanced head and neck squamous cell carcinoma (AJCC 8th Edition Staging). 4. According to the RECIST 1.1 tumor evaluation criteria, it has at least one measurable lesion; 5. There was no history of immunosuppressant treatment within 6 months prior to inclusion in the study; 6. Eastern Cooperative Oncology Group physical fitness of all patients The status score is 0 or 1 (on a 5-point scale, with a higher score indicating more severe disability), and organ function is normal. During the study period, patients must submit tumor tissue or blood samples from before treatment. 8. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with distant metastases (screening measures: chest radiograph, PET-CT/MR, abdominal B-ultrasound); 2.Heart, lung and other poor function, hematopoietic dysfunction or other physical factors can not complete the treatment or refuse new supplements Adjuvant chemotherapy, adabilimab and other treatments; 3.Including but not limited to systemic lupus erythematosus, Behcet's disease, Sjogren's syndrome and other known or suspected self People with immune disease, uncontrolled disease, or other active infectious disease; 4.Need to be on immunosuppressive drugs or have a chronic infection (e.g., human immunodeficiency virus, hepatitis B disease) Virus or hepatitis C virus infection) in the active stage of the disease; 5.A history of other malignancies within the previous 5 years (excluding cured cervical carcinoma in situ and skin basal cells) Cancer) or in conjunction with other anti-tumor therapy (including anti-tumor immunotherapy) or participate in other clinical interventions trier; 6.Pregnant and lactating women; 7.Previous allogeneic bone marrow transplantation or solid organ transplantation;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year local control rate;Progression free survival;Overall survival rate;Complication; | — |
Countries
China
Contacts
Public ContactWenbin Lei
The First Affiliated Hospital,Sun Yat-sen University
Outcome results
None listed